Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2025
Reporting Period: Event-based disclosure regarding clinical trial updates.
Business Focus: The Company is an emerging growth company developing intranasal NEO100 for the treatment of recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change disclosed is the announcement of updated clinical results from the Company's ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100. No financial material changes were reported in this document.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release (Exhibit 99.1) detailing updated clinical data for NEO100 in patients with specific brain tumor mutations.
- Regulatory Status: The information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Risks: As an emerging growth company, the registrant is subject to reduced reporting requirements, though no specific new risks were detailed in the text of this 8-K beyond the inherent uncertainties of clinical development.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific clinical data points and patient outcomes regarding NEO100.
- Verify the status of the Phase 1/2a trial and compassionate-use program in subsequent regulatory filings.
- Check the Company's most recent 10-K or 10-Q for current liquidity and cash runway, as this 8-K contains no financial data.
- Confirm the trading status of NTHI on The Nasdaq Stock Market LLC.